Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Elinoar, Rahat, Michal A., Feld, Joy, Elias, Muna, Rosner, Itzhak, Kaly, Lisa, Lavie, Idit, Gazitt, Tal, Zisman, Devy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770905/
https://www.ncbi.nlm.nih.gov/pubmed/31540528
http://dx.doi.org/10.3390/ijms20184633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770905/
https://www.ncbi.nlm.nih.gov/pubmed/31540528
http://dx.doi.org/10.3390/ijms20184633

Ejemplares similares